Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Exclusion Criteria14

• Prior history of MI / PCI / coronary artery bypass graft (CABG) within previous 1 year
• Patients with previous history of left ventricular ejection fraction (LVEF) < 40%
• Use of investigational drugs or devices 30 days prior to randomization
• Known allergy or contra-indication to gadolinium/contrast agents
• eGFR < 30 ml/kg/min
• Any contraindication against cardiac MRI (such as metal implants)
• Women who are pregnant or breastfeeding. Women of reproductive potential must have a negative pregnancy test prior to randomization
• Body weight > 140 kg (or 309 lbs.)
• Absolute neutrophil count - ANC < 1.5 k/cumm
• History of Chronic Liver Disease
• Elevated hepatic enzymes (BOTH ALT and AST) > 2 times of upper normal limit
• Patients with iron storage disease (hemochromatosis, thalassemia) or who are already treated with iron chelators
• Any clinically significant abnormality identified prior to randomization that in the judgment of the Sponsor-Investigator or Delegate would preclude safe completion of the study or confound the anticipated benefit of deferiprone.
• Life expectancy of less than 1 year due to non-cardiac pathology